Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

New Ovarian Transplant Technique Could Expand Use Of Procedure To Preserve Fertility
Two recent advancements in ovarian transplant techniques could potentially expand the availability of the procedure for women seeking to avoid fertility problems as they age, researchers reported Monday at a meeting of the European Society of Human Reproduction and Embryology, the AP/Yahoo! News reports. According to the AP/Yahoo! News, ovary transplants traditionally have been performed on women with cancer as a method of preserving fertility after chemotherapy or other treatments that can affect the reproductive system. The procedure involves removing the ovaries before treatment and re-implanting them after treatment is complete. Because only a handful of these procedures have been successful, ovarian transplants have been an option only for women with serious diseases. However, as more women delay having children until their 30s or 40s, researchers say the new techniques, in theory, could make it simpler for healthy younger women to have an ovary removed, frozen and then re-implanted later in life when they are ready to have children.The first study examined how many eggs were lost or preserved in fresh and frozen ovarian tissue of 15 young women prior to the start of cancer treatment. According to the study, there was no difference in the quantity of eggs in the fresh tissue and in the ovaries frozen using a new ultra-fast technique. The study found that about 50% of a woman"s eggs were lost using the traditional, slow-freezing methods of preserving the ovaries.The second study reported on a new surgical technique to restore an ovary"s function after transplantation. For the study, Pascal Piver of Limoges University Hospital and colleagues divided the transplant process into two separate procedures in an attempt to more quickly re-establish blood and hormone supplies to the ovary. In the first procedure, the researchers performed a graft of small pieces of ovarian tissue to prompt blood vessels to grow. They performed the ovary transplant three days later. The technique was successful in a woman who lost fertility because of treatment for sickle cell anemia.Sherman Silber, director of the St. Louis Infertility Center in Missouri and a researcher for the first study, said the new techniques "could dramatically expand our reproductive life span." He added, "This is not an experimental procedure for cancer patients anymore. The question is whether more women should be able to have this option" (Cheng, AP/Yahoo! News, 6/29).
generic viagra online
Liverpool To Strengthen Health Research In Africa
Researchers at the Liverpool School of Tropical Medicine (LSTM) and the University of Liverpool will work with universities across Africa as part of a ÷£30 million initiative to strengthen research into science and health on the continent.
News of the day
Diet To Reduce Mild Hyperoxaluria In Patients With Idiopathic Calcium Oxalate Stone Formation: A Pilot Study
UroToday.com - You pass what you eat! If you eat wisely, passage shouldn"t be painful. This may be especially true for stone formers. To be sure, high fluid intake resulting in a urine output of > 2 liters per day is key; however, what is eaten also plays a role. In this study among 56 hyperoxaluric patients on a low oxalate diet, the institution of a low salt (4-5 grams/day), low animal protein (approximately 20 grams per day vs. a norm of 50 grams per day), and normal calcium diet over a 3 month period, resulted in a statistically significant drop in 24 hour urine calcium (364 to 263 mg/d) and oxalate (50 to 35 mg/d).
Medical Devices

Neupro(R) (rotigotine Transdermal Patch) Can Now Be Prescribed To All Patients With Idiopathic Parkinson's Disease In Europe

UCB announced that Neupro(R) (rotigotine transdermal patch) can now be prescribed to all patients with idiopathic Parkinson"s disease in Europe and is newly available for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) in adults. This follows the decision of the European Commission to lift treatment restrictions on Neupro® in line with the recommendation of the European Medicines Agency (EMEA), issued on 29 May 2009. "We are delighted that all patients with Parkinson"s disease in Europe can once again benefit from continuous drug delivery and the improvement in symptoms that is offered with Neupro® and that, for the first time, people with RLS in Europe will also experience the advantages of this important treatment," said Troy Cox, Senior Vice President CNS Operations, UCB. Since June 2008, Neupro® supply in Europe has been limited to patients already established on the drug while a new cold-chain storage and distribution system was developed to meet the need for refrigeration of the product from manufacturer to patient. Following full implementation of this system, refrigerated stocks of Neupro® are available in all doses so Neupro® can be prescribed by European physicians for all patients with idiopathic Parkinson"s disease. Neupro® in Parkinson"s disease Parkinson"s disease affects over six million people worldwide and approximately three million patients in the seven major markets (U.S., Japan, Germany, UK, France, Italy and Spain). Formulated as a once-a-day transdermal patch, Neupro® continuous drug delivery provides stable drug levels in the bloodstream. Neupro® provides statistically significant and clinically relevant improvements in movement and ability to carry out everyday activities in people with early-stage Parkinson"s disease and significantly reduces off time and increases on time in people with later stage Parkinson"s disease. Neupro® is generally well-tolerated. Adverse drug reactions reported in more than 10% of Parkinson"s patients treated with Neupro® are nausea, dizziness, somnolence and application site reactions. Neupro® in RLS In August 2008, the European Commission approved Neupro® for the symptomatic treatment of idiopathic moderate to severe RLS in adults. The UK and Germany are the first European countries to launch Neupro® (1 mg/24 h, 2 mg/24 h and 3 mg/24 h) in this new indication. RLS affects between 3 and 10% of the population to some extent. In a clinical trial of 458 patients with moderate to severe RLS, Neupro® (1 mg/24 h, 2 mg/24 h and 3 mg/24 h dose) proved more efficacious than placebo in relieving bedtime, night and daytime symptoms in patients over a six month treatment period. Neupro® was shown to reduce symptoms by >=50% in over half of patients (54.2%) compared to symptom reduction in approximately one third (29.9%) of patients on placebo. In addition more patients receiving Neupro® (3 mg/24 h) achieved clinical remission (47.3% vs. 22.8% placebo) and symptom freedom (31.3% vs. 12.3% placebo). "We look forward to having Neupro® available as a new treatment option for RLS patients. The results of this rotigotine trial demonstrated efficacy, increased opportunity for symptom freedom in moderate to severely affected RLS patients and improvements to patients" quality of life" said Dr Claudia Trenkwalder from the Paracelsus-Elena Hospital, Kassel, Germany and lead investigator of the study. UCB


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009